Hey George, and Welcome:
This is the news release put out by Paracelsian a couple weeks ago:
Paracelsian Signs CRADA with NCI to Evaluate the Role of Signal
Transduction Pathways in Malignant Cell Growth and in Cell
Death
The Goal of this Collaboration is to Develop New Drug Designs for Future
Anti-Cancer
and Anti-HIV Therapies
ITHACA, N.Y., Jan. 13 /PRNewswire/ -- Paracelsian Inc reported that it signed a
definitive Cooperative
Research And Development Agreement (CRADA) with the laboratory of Tumor Cell
Biology of the National
Cancer Institute (NCI). This cooperative agreement extends the previously successful
relationship between the
NCI and Paracelsian by building upon the original letter of intent, according to Dr.
John Babish, Vice President
and Chief Science Officer.
The specific objectives of this CRADA will be to screen for unique, pharmacological
agents from the
Company's library of herb extracts used in traditional Chinese medicine ("TCMs") for
their capability of
modulating a cell signaling pathway induced in certain HIV and Pancreatic, Kaposi's
Sarcoma and Breast
Cancer cell lines developed by NCI. And secondly, the CRADA will seek to develop
an understanding of the
molecular interactions of the various screen-positive TCMs with the cell signaling
pathways in the cell. A
detailed knowledge of these interactions will be useful for potential future molecular
modeling and design of
improved therapeutics.
Under the CRADA, the NCI principal investigator is Dr. Genoveffa Franchini and the
NCI Co-Investigator is Dr.
David I. Cohen. The principal investigator for the Company is Dr. John Babish. Work
on this project
commenced during 1995 under a letter of intent and the agreement carries a term of
two years through
December 1998.
Commenting on the CRADA, Dr. Babish said, "The potential of the work has already
been demonstrated with
the description of a kinase pathway in HIV killing of the immune system by Dr. Cohen.
We see this
collaboration as a way to further AIDS and Cancer research on a world-class basis.
This Agreement also gives
the Company a way to screen its library of extracts used in traditional Chinese
medicine for potential new
dietary supplements and drugs beyond the Company's internally developed proprietary
screening process."
Dr. Cohen of the NCI added, "The company's recent study of AndroVir(TM) in HIV
infected individuals is very
promising following the results we have observed in the laboratory. We are very
encouraged by the results
obtained in the human trial, including the reductions in viral loads and the increases in
CD4+ cell counts of the
subjects in such a short period of time. As our collaboration continues from here, the
potential for product
discovery and enhanced new drug design is exciting and could spur development of
widely used therapies. We
are all looking forward to a productive collaboration under this CRADA."
The Company has been invited to present at the up-coming Smith Barney "Fifth Annual
Health Care Services
Conference" in New York City on February 10-14. It plans to present the scientific
progress under this CRADA
and the recent results of initial clinical trials of products as dietary supplements for HIV
and cancer patients. It
also plans to outline the 1997 product launch plans for AndroVir(TM) and
AndroCar(TM) as diet supplements.
Interested persons unable to attend are invited to contact the Company after the
conference to receive an
information kit covering the topics presented.
Paracelsian is a biotechnology company engaged in the discovery of useful products
from herbal sources. Its
discoveries are accomplished by applying the Company's proprietary screening
technology, based in signal
transduction, to its library of extracts used in Traditional Chinese Medicine. Paracelsian
recently announced
plans to launch its first dietary supplement products in 1997; AndroVir(TM) in support
of normal immune
function and AndroCar(TM) to support the general well being in cancer patients.
SOURCE Paracelsian, Inc.
George: This is my own personal comment. Paracelsian is not for the faint of heart. Paracelsian is for the risk adverse who REALLY believe there is a better way of treating AIDS and Cancer patients using traditional chineese medicines. Most of us are strong believers, and if things work out, the company and the stock is going to be 1997's mega winner. They are set to go production in 1997 for their two herbal supllements which have shown good results against AIDS and cancer (maybe someone can find the press releases).
If not, Paracelsian could be your 1997 tax loss..
I'll tell you and t36 more about the stock later today, but I would definately suggest reading this thread, and reading the press releases.
Rick Davis |
